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Abstract. It has recently become popular to define treatment effects
for subsets of the target population characterized by variables not ob-
servable at the time a treatment decision is made. Characterizing and
estimating such treatment effects is tricky; the most popular but naive
approach inappropriately adjusts for variables affected by treatment
and so is biased. We consider several appropriate ways to formalize
the effects: principal stratification, stratification on a single potential
auxiliary variable, stratification on an observed auxiliary variable and
stratification on expected levels of auxiliary variables. We then outline
identifying assumptions for each type of estimand. We evaluate the util-
ity of these estimands and estimation procedures for decision making
and understanding causal processes, contrasting them with the con-
cepts of direct and indirect effects. We motivate our development with
examples from nephrology and cancer screening, and use simulated data
and real data on cancer screening to illustrate the estimation methods.
Key words and phrases: Causality, direct effects, interaction, effect
modification, bias, principal stratification.
Marshall M. Joffe is Associate Professor, Department
of Biostatistics and Epidemiology, University of
Pennsylvania School of Medicine, Philadelphia,
Pennsylvania 19104-6021, USA e-mail:
mjoffe@mail.med.upenn.edu. Dylan Small is Assistant
Professor, Department of Statistics, The Wharton
School, University of Pennsylvania, Philadelphia,
Pennsylvania 19104-6340, USA e-mail:
dsmall@wharton.upenn.edu. Chi-Yuan Hsu is Assistant
Professor in Residence, Division of Nephrology,
University of California, San Francisco, San Francisco,
California 94143, USA e-mail:
hsuchi@medicine.ucsf.edu.
This is an electronic reprint of the original article
published by the Institute of Mathematical Statistics in
Statistical Science, 2007, Vol. 22, No. 1, 74–97. This
reprint differs from the original in pagination and
typographic detail.
1. INTRODUCTION
In the recent literature on causal inference, it has
become popular to define treatment effects for sub-
sets of the target population characterized by vari-
ables not observable at the time a treatment deci-
sion is made. The most popular framework for do-
ing this is principal stratification (PS); this name
was introduced in a unifying paper by Frangakis
and Rubin (2002). The ideas have been applied to
a broad range of problems, including censoring by
death (Robins, 1986; Zhang and Rubin, 2003), non-
compliance in randomized trials (Angrist, Imbens
and Rubin, 1996; Baker and Lindeman, 1994), the
estimation of the effects of vaccines on post-infection
outcomes (Gilbert, Bosch and Hudgens, 2003) and
surrogate outcomes in randomized trials (Frangakis
and Rubin, 2002). As we shall see, PS is one of sev-
eral possible ways to define these effects.
The reasons for interest in effects defined by post-
treatment auxiliary variables are diverse. We con-
sider two problems, one in nephrology and one in
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cancer screening, to provide motivation for inter-
est in these various estimands and estimation pro-
cedures.
Nephrologists have been frustrated by the lack of
a good means to lower the high rates of morbid-
ity and mortality among patients after the onset of
end-stage renal disease (ESRD), the point at which
kidney disease has progressed sufficiently to require
dialysis treatment. Suggested methods to reduce this
morbidity and mortality, which have included bet-
ter or more aggressive control of anemia and higher
doses of dialysis, have shown disappointing results
(Paniagua, Amato, Vonesh, Correa-Rotter, Ramos,
Moran and Mujais, 2002; Eknoyan, Beck, Cheung,
Daugirdas, Greene, Kusek, Allon, Bailey, Delmez,
Depner, Dwyer, Levey, Levin, Milford, Ornt, Rocco,
Schulman, Schwab, Teehan and Toto, 2002; Besarab,
Bolton, Browne, Egrie, Nissenson, Okamoto, Schwab
and Goodkin, 1998). Frustration with the inability
of treatments or interventions given after the initia-
tion of dialysis to affect the course of ESRD has led
some to hypothesize that the period before ESRD
develops may provide a window of opportunity to
improve outcomes among ESRD patients. The hope
is that interventions or treatments applied before
ESRD develops may affect the clinical course after
development of ESRD; that is, it is hypothesized
that treatments given before ESRD affect outcomes
after the development of ESRD.
This apparently simple hypothesis is surprisingly
hard to formalize. The difficulty stems from the fact
that not all subjects with advanced chronic renal
insufficiency (CRI) progress to ESRD, and that the
same interventions that may affect outcomes after
the onset of ESRD may themselves help determine
who will develop ESRD. After considering a naive
approach and illustrating its difficulties (Section 2),
this paper considers several ways to formalize the
hypothesis; for each, we briefly consider approaches
to estimation of relevant and causally meaningful
parameters (Section 3).
A second motivating problem concerns evaluation
of the efficacy of cancer screening. Successful meth-
ods for screening for cancer result in earlier diagnosis
of cancer (or precancerous conditions); this early de-
tection may lead to treatment of the cancer while the
cancer is still curable and so to reduced mortality.
Randomized trials have been used to evaluate cancer
screening; often, people randomized to screen fail to
comply with their assignment. It is expected that
any benefit of assignment to screening would be re-
stricted to women who are screened. It might further
be surmised that any benefit of screening would be
restricted to screened women diagnosed with breast
cancer and that the benefit of screening would be
restricted even further to women whose cancer was
diagnosed as a result of the screen. For explanatory
purposes, it is of interest to estimate the benefit of
screening for women in these subgroups. Hypotheses
here may be formulated in ways similar to those in
the nephrology problem. In these data, the outcome
is failure-time, a censored continuous variable.
In Section 4 we consider statistical inference. We
consider ranges of assumptions that identify the var-
ious estimands, as well as methods of estimation.
Where necessary, we concentrate on continuous out-
comes, as some methods for inference are more
straightforward here. In Section 5 we consider a sim-
ulation experiment to provide some comparison of
inference under various approaches. In Section 6 we
analyze data about cancer screening from the Health
Insurance Plan (HIP) Study (Shapiro, Venet, Strax
and Venet, 1988), considering various estimands of
interest.
In Section 7 we evaluate and compare the various
approaches in terms of their utility for decision mak-
ing and explanation. In addition, we compare the
approaches conditioning treatment effects on post-
treatment auxiliary variables to the estimation of di-
rect and indirect effects. The paper concludes with
discussion of extensions of the estimands and meth-
ods to more complex settings.
2. MOTIVATING EXAMPLE: DATA AND
SIMPLE ANALYSIS
2.1 Data and Potential Outcomes
Wemotivate our methodological development with
a simple numerical example. The example is from a
study in a cohort of subjects with chronic renal in-
sufficiency, a condition in which subjects have di-
minished kidney function but do not yet require
dialysis or transplant (Feldman, Appel, Chertow,
Cifelli, Cizman, Daugirdas, Fink, Franklin-Becker,
Go, Hamm, He, Hostetter, Hsu, Jamerson, Joffe,
Kusek, Landis, Lash, Miller, Mohler, Muntner, Ojo,
Rahman, Townsend andWright, 2003); although the
numbers are arbitrary, they are intended to repre-
sent, in simplified fashion, the problems and associ-
ations present in studying effects in this population.
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Here, we wish to study the effect of aggressive treat-
ment of hypertension on myocardial infarction (MI)
among subjects who develop ESRD after the start
of follow-up. We make several simplifying assump-
tions, which we do not necessarily expect to apply
in real data:
1. each of our main study variables is binary and
scalar;
2. subjects are randomly assigned to either receive
or not receive aggressive management of hyper-
tension;
3. no subject has ESRD at the start of follow-up;
and
4. subsequent ESRD status is recorded before any
MI occurs.
We use A to refer to the treatment of interest [A=
1 (0) indicates the presence (absence) of aggres-
sive treatment of hypertension], S to denote a post-
treatment auxiliary variable [S = 1 (0) indicates the
presence (absence) of ESRD] and Y to refer to the
outcome of interest [Y = 1 (0) indicates the occur-
rence (absence of occurrence) of an MI before the
end of follow-up].
We adopt the potential outcomes approach (Ney-
man, 1990; Rubin, 1974) to illustrate and define
our causal estimands of interest. Let Y a denote the
outcome that would be seen were a subject given
treatment level a and let Sa denote the level of the
auxiliary variable were a subject given treatment a.
Causal effects are normally defined in terms of com-
parisons of the outcomes that would be seen in the
same individuals or groups under different condi-
tions; for example, as comparisons of Y a and Y a
′
for
a 6= a′. For this illustration, we assume that aggres-
sive treatment does not affect MI for any individual
(i.e., that Y 0 = Y 1 for all subjects); however, aggres-
sive treatment will prevent ESRD for some subjects
but never cause it, and so S1 ≤ S0.
Table 1 classifies the population according to
whether they would develop ESRD if treated and
if untreated, and considers the risk of failure in all
strata based on the cross-classification of this auxil-
iary variable. Half of the population would not de-
velop ESRD whether or not they were treated (i.e.,
S0 = S1 = 0); the risk of MI in this group is low
(10%). In another 30% of the population, aggressive
treatment would prevent ESRD (i.e., S1 = 0, S0 =
1); the risk of MI in this group is higher (20%). The
risk is highest (30%) in the 20% of the population
doomed to get ESRD regardless of treatment (i.e.,
S1 = 1, S0 = 1).
In any study, we cannot simultaneously observe
what would happen to any individual under aggres-
sive treatment (Y 1, S1) and in its absence (Y 0, S0),
and so the joint distribution of the variables repre-
sented in Table 1 is not estimable. Table 2 shows
what would be observed in a randomized trial in
which half of the subjects receive aggressive treat-
ment and half do not. Because 30% of subjects in
the cohort would develop ESRD only if not treated
aggressively (Table 1, row 2), the proportion of sub-
jects treated aggressively who develop ESRD (20%=
100/500) is much lower than the proportion of sub-
jects not treated aggressively who develop ESRD
(50% = 250/500). Among untreated subjects who
develop ESRD, 24% develop an MI, whereas 30% of
treated subjects who develop ESRD also develop an
MI. Similarly, 10% of untreated subjects who do not
develop ESRD later develop an MI, whereas 13.75%
of treated subjects who do not develop ESRD later
develop an MI. All of this may be derived (in expec-
tation) from Table 1.
2.2 A Naive Approach
To examine the effect of aggressive treatment on
MI among subjects who develop ESRD, some would
compare the probability of MI among aggressively
treated subjects who develop ESRD (0.3) with the
probability of MI among untreated subjects who de-
velop ESRD (0.24). A naive interpretation is that
Table 1
Probability of MI if treated aggressively or not, by ESRD status if treated aggressively or not
ESRD status Probability of MI
if untreated (S0) if treated (S1) pr(Y 0 = 1|S0, S1) pr(Y 1 = 1|S0, S1) N
0 0 0.1 0.1 500
1 0 0.2 0.2 300
1 1 0.3 0.3 200
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Table 2
Probability of MI in randomized trial, by treatment arm
and observed ESRD status
Treatment (A) ESRD (S) N Probability of MI
(pr(Y = 1|S, A))
0 0 250 0.1
1 250 0.24
1 0 400 0.1375
1 100 0.3
the difference between these probabilities (0.06) rep-
resents the effect of treatment for subjects who will
develop ESRD. This interpretation is not correct,
since aggressive treatment actually has no effect on
MI for any subject. The naive comparison pr(Y =
1|A = 1, S = 1) − pr(Y = 1|A = 0, S = 1) diverges
from the true individual causal effects because mem-
bership in the groups being compared depends on
treatment. Aggressive treatment reduces the num-
ber of subjects with ESRD. Subjects who would de-
velop ESRD even if treated aggressively comprise
the sickest subgroup in the study. A higher propor-
tion of them than any other subgroup would have
developed MI whether or not they had received ag-
gressive treatment, and comparing them with un-
treated subjects who develop ESRD is comparing
them to a combination of subjects from the same
subgroup and subjects who would develop ESRD
only if not treated aggressively. Thus, condition-
ing on ESRD, a post-treatment variable, leads to
inappropriate estimates of overall treatment effect
(Robins, Blevins, Ritter and Wulfsohn, 1992; Rosen-
baum, 1984).
A complementary approach to view the bias re-
sulting from conditioning on ESRD involves directed
acyclic graphs (DAGs) (Pearl, 1995, 2000). Figure 1
shows the relations between the observed variables
A,S and Y , and unobserved variable(s) U . The ar-
rows from U to both S and Y indicate that there
Fig. 1. A directed acyclic graph representing the relations
among the variables in the example of Section 2.
are some unmeasured common causes of both. The
arrow from A to S indicates that A influences S,
whereas the absence of any directed path (i.e., a se-
ries of directed arrows) from exposure to outcome
indicates that A has no effect on Y . S is known
as a collider (i.e., there are arrows which converge
on S). It is well known that conditioning on col-
liders induces associations between the parents of
the collider (i.e., between A and U ). Because U in-
fluences Y , the conditional association between A
and U given S propagates to a conditional associ-
ation between A and Y given S. Structurally simi-
lar problems involving selection bias in epidemiology
are discussed elsewhere (Greenland, 2003; Herna´n,
Herna´ndez-Dia´z and Robins, 2004).
We consider briefly an appropriate causal inter-
pretation of the naive comparison of observable con-
ditional distributions pr(Y = 1|A= 1, S = 1)−pr(Y =
1|A= 0, S = 1). In a randomized trial, the observed
distribution pr(Y |A = a,S = s) equals the condi-
tional distribution pr(Y a|Sa = s) of the potential
outcome that would be seen among subjects who
would have a common value of the auxiliary vari-
able S if they receive level a of treatment. Here,
this is the probability of MI that would be seen
in subjects developing ESRD were all subjects to
be treated aggressively (for a = 1) or not receive
aggressive treatment (for a = 0). A comparison of
pr(Y a|Sa = s) for different values of treatment a re-
flects the impact of treatment on the conditional
distribution of the potential outcome given the aux-
iliary outcome. In nonrandomized studies, the ob-
served conditional distributions pr(Y |A = a,S = s)
will not in general equal the potential conditional
distributions pr(Y a|Sa = s). So long as information
is collected on all subjects in a cohort, this condi-
tional distribution is identified under the commonly
used assumption of strongly ignorable treatment as-
signment (Rosenbaum and Rubin, 1983),
pr(A= a|S,Y ,X) = pr(A= a|X)> 0,(1)
where S ≡ {Sa} and Y ≡ {Y a} denote the vectors
of potential auxiliary and main outcomes, respec-
tively. Strong ignorability identifies pr(Y a|X,Sa =
s) as pr(Y |X,A = a,S = s). The potential condi-
tional distributions may be useful in decision mak-
ing (Section 7.1).
Sometimes, the effects of an intervention on a (con-
ditional) distribution will be all that is identifiable
from one’s data under plausible assumptions. Here,
however, there are other measures of effect that more
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closely relate to the scientific questions of interest,
regarding the effect that aggressive treatment has
for subjects who develop ESRD. We consider these
in the following sections.
3. DEFINITION OF EFFECTS FOR A
COMMON SET OF INDIVIDUALS
We consider several ways of characterizing or defin-
ing effects for subjects who will develop (or are likely
to develop) an auxiliary outcome. In each approach,
we consider first the group or subgroup for whom
effects are defined; for each approach, the definition
of effects for this group follows in a straightforward
way from the potential outcomes approach. We re-
late the effects to each other through a common
probability model in Section 3.7.
3.1 Principal Stratification
Principal stratification (PS) (Frangakis and Ru-
bin, 2002) is a method proposed recently by several
authors for defining certain types of causal effects. In
this approach, effects are characterized within strata
defined by the vector of potential auxiliary outcomes
(here S0 and S1). In our example, we may be inter-
ested in the effect of aggressive treatment for sub-
jects who would develop ESRD whether or not they
are treated aggressively (i.e., S0 = S1 = 1). In par-
ticular, we concentrate here on comparing the pro-
portion in this subgroup that would have an MI if
treated aggressively [pr(Y 1 = 1|S0 = S1 = 1)] and
the proportion in the same subgroup who would
have an MI if not treated aggressively [pr(Y 0 = 1|S0 =
S1 = 1)]. In general, the approach compares the ex-
pected value or distribution of potential outcome Y a
for different levels of treatment (a = 0,1) in strata
defined by the levels the auxiliary variable would
take under both levels of treatment (i.e., strata are
defined by S0 and S1 jointly). In our data, this stra-
tum is shown in the third data row of Table 1; ag-
gressive treatment has no effect on MI in this group
(as in all other principal strata).
In general, the principal strata are not fully iden-
tified from the data, because one cannot simulta-
neously observe both potential auxiliary outcomes
S0 and S1. In the data in Table 1, aggressive treat-
ment sometimes prevents but never causes ESRD
(i.e., S0 ≥ S1); this monotonicity (Angrist, Imbens
and Rubin, 1996) is not completely plausible in the
nephrology example; Section 8.1 discusses this at
more length. Under monotonicity, the principal stra-
tum of some subjects is identifiable: aggressively
treated subjects who develop ESRD would have done
so even had they not been treated (i.e., A= 1, S =
S1 = 1 implies S0 = S1 = 1), and untreated subjects
who do not develop ESRD would not have done so
even had they been treated (i.e., A= 0, S = S0 = 0
implies S1 = S0 = 0).
3.2 Single Potential Stratification
One can define the effect of a treatment for a sub-
group defined by a single potential outcome. For ex-
ample, one may be interested in the effect of ag-
gressive treatment for people who would develop
ESRD if they were treated aggressively [a compari-
son of pr(Y 1 = 1|S1 = 1) and pr(Y 0 = 1|S1 = 1); Ta-
ble 1, row 3], or in the effect of aggressive treatment
on people who would develop ESRD if they were
not treated aggressively [a comparison of pr(Y 1 =
1|S0 = 1) and pr(Y 0 = 1|S0 = 1); the last two rows
in Table 1]. Such stratification may be viewed as a
coarser form of PS.
Membership in this stratum, defined by a single
auxiliary variable (S0 or S1), is only partially ob-
served. Whether a person is in this single auxiliary
stratum defined by Sa is known if a person receives
treatment level a. As above, this complicates sta-
tistical inference for effects defined for such groups.
One may use approaches such as those used for PS
to estimate effects defined in this fashion; because
of the connection with observed auxiliary stratifi-
cation, one can also use methods described for the
next sort of stratification we discuss.
3.3 Observed Auxiliary Stratification
For this approach, we define effects for groups de-
fined by observed auxiliary variables. For example,
we might consider the effect of aggressive treatment
for subjects who received nonaggressive treatment
and developed ESRD; that is, we compare pr(Y 1 =
1|S = 1,A = 0) with pr(Y 0 = 1|S = 1,A = 0). The
subjects for whom this effect is defined are the 250
subjects in the second row of Table 2 (who comprise
the 50% of the subjects in the second and third rows
of Table 1 who are untreated). Alternatively, we
might be interested in the effect of aggressive treat-
ment for subjects who received aggressive treatment
and developed ESRD; that is, we compare pr(Y 1 =
1|S = 1,A= 1) with pr(Y 0 = 1|S = 1,A = 1) (here,
the effects are defined for the last row of Table 2, or
the 50% of the last row of Table 1 who are treated).
We have called the latter comparison the realized ef-
fect of treatment (Joffe, 2001), because it represents
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the effect treatment actually had within a subgroup
(which, in this instance, is defined by post-treatment
variables).
In a randomized trial, observed auxiliary strat-
ification is equivalent to single potential auxiliary
stratification. To see this, note that pr(Y a
′
= 1|S =
1,A = a) = pr(Y a
′
= 1|Sa = 1,A = a) = pr(Y a
′
=
1|Sa = 1); the last step follows because of random-
ization. Thus, for example, in a randomized trial
in our ESRD example, aggressively treated subjects
who develop ESRD are comparable to the set of sub-
jects who, if they had received aggressive treatment,
would have developed ESRD. In observational stud-
ies, under ignorable treatment assignment (Rosen-
baum and Rubin, 1983), the above holds conditional
on covariates.
Here, the subgroup for whom the effect is defined
is fully observable; however, the effects are defined
for groups that are not identified at time of treat-
ment decision. Thus, like PS and single potential
stratification, this approach cannot be used directly
to predict, at the time of a treatment decision, the
effect of that decision. Further, there is an explana-
tory flavor to the analysis and model: these effects,
which have already happened to defined subgroups,
can be used to explain differences between random-
ized groups.
3.4 Expected Auxiliary Stratification
Unlike previous approaches, one can define effects
in a way that uses information on auxiliary variables
to define subgroups identifiable at the time treat-
ment decisions are made. Here, we define effects for a
group of subjects who are likely to develop ESRD if
given a particular treatment. Let µa(X)≡E(Sa|X)
denote the probability, given baseline covariates X ,
of developing ESRD if one were to receive treatment
level a; it is the expected value of the potential aux-
iliary variable. µa(X) has been called a “principal
score” (Hill, Waldfogel and Brooks-Gunn, 2002). We
then define effects as a comparison of potential out-
comes (MI) for subjects with the same expected aux-
iliary (ESRD), for example, E{Y 1|µ1(X)} −
E{Y 0|µ1(X)}. Alternatively, we can define effects
for broader strata based on µa(X), for example,
E{Y 1|µ1(X)> 0.8}−E{Y 0|µ1(X)> 0.8}, the effect
of aggressive treatment for subjects with at least an
80% chance of developing ESRD if treated aggres-
sively.
3.5 Expected Multiple Auxiliary Stratification
The approach of the last section may be extended
to condition effects on multiple expected auxiliary
variables. Thus, one might be interested in the effect
of treatment for subjects with an 80% risk of devel-
oping ESRD if treated aggressively and a 90% risk if
not treated aggressively; that is, we derive effects for
subjects based in groups determined by both µ0(X)
and µ1(X). This approach has the flavor of PS; un-
like PS, the subgroups for whom effects are defined
are fully identified in the data, based solely on pre-
treatment information. As in the previous section,
conventional statistical methods apply.
3.6 Conventional Approach
A final alternative is to estimate effects in sub-
groups based solely on pretreatment covariates, where
group membership is not dependent on any risk score
like µa(X). Conventional estimation approaches may
apply; we may look for effect modification by base-
line covariates directly, rather than indirectly through
the expected auxiliary.
3.7 Probability Models for the Data
Following Rubin (1978), we consider a formal prob-
ability model for the joint distribution of the observ-
able data and potential outcomes. We then consider
approaches to parametrizing parts of this distribu-
tion (Section 4).
One general way to factor the joint density of the
observable quantities and potential outcomes is
f(X,S,Y ,A)
(2)
= f(X)f(S|X)f(Y |X,S)f(A|X,S,Y ).
This factorization is akin to selection models in com-
mon use in longitudinal data analysis (Little, 1995).
Strongly ignorable treatment assignment (Rosenbaum
and Rubin, 1983) is often assumed.
PS estimands depend only on one part of the joint
density: f(Y |X,S). Other causal estimands also in-
volve the density of the auxiliary outcome (and some-
times of the exposure). Single potential stratification
estimands involve f(Y |X,Sa). These estimands can
be obtained by integrating out the other potential
auxiliary outcomes; that is, f(Y |X,Sa) =
∫
S¬a f(Y |X,
S)f(S|X)ds¬a/f(Sa|X), where S¬a refers to the vec-
tor of unobserved potential auxiliary outcomes. Ob-
served auxiliary estimands involve f(Y |X,S,A) =
f(Y ,A|X,S)/f(A|X,S) =
∫
S¬a f(Y |X,S)f(S|X) ·
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f(A|X,S,Y )dS¬a/
∫
S¬a
∫
Y f(Y |X,S)f(S|X)f(A|X,
S,Y )dS¬a dY ; under ignorability, this simplifies to
f(Y |X,S,A = a) =
∫
S¬a f(Y |X,S)f(S|X)ds
¬a/
f(Sa|X), which is the estimand of single potential
stratification. Expected auxiliary stratification in-
volves integrating out all the auxiliary potential out-
comes; that is,
f{Y |E(Sa|X) = s}
=
∫
X:E(Sa|X)=s
∫
S f(Y |X,S)f(S|X)f(X)dS dX∫
X:E(Sa|X)=s f(X)dX
=
∫
X:E(Sa|X)=s f(Y |X)f(X)dX∫
X:E(Sa|X)=s f(X)dX
;
in this formulation, one can ignore the density of
the auxiliary outcome except as it relates to identi-
fying the subset over whom to average. Similarly, in
stratifying on observed variables, one can integrate
out and ignore the auxiliary outcome: f(Y |X) =∫
S f(Y |X,S)f(S|X)dX . Typically, inference concen-
trates on comparisons of the marginal densities
f(Y a|X, ·) of the potential outcomes for different
treatment levels a, rather than the joint density
f(Y |X, ·) of the potential outcomes Y .
4. CONTINUOUS OUTCOMES: MODELS
AND ESTIMATION
This section considers statistical inference about
the various estimands outlined in the previous sec-
tion. Some estimation methods in this setting are
more straightforward with continuous outcome data,
and so we discuss models and estimation methods
more fully for such data. We apply these methods
both to simulated data (Section 5) and the HIP data
(Section 6).
We now discuss estimation of the various causal
quantities defined in the previous sections, concen-
trating on identification of causal contrasts. We re-
verse the order of discussion, beginning with strat-
ification on observed variables and ending with PS,
as the nature of the latent structure and identify-
ing assumptions becomes increasingly complex. The
greater the degree of latent structure, the more as-
sumptions are needed to estimate parameters in the
model. The greater degree of assumptions involved
is justified if they lead to better decision making,
more explanatory power or greater generalizability,
issues we take up in Section 7.
4.1 Conventional Approaches
For the conventional approach, identification of
the marginal distributions f(Y a|X) may be based
on the assumption of ignorable treatment assign-
ment (Rosenbaum and Rubin, 1983), pr(A = a|
X,Y ) = pr(A= a|X), with 0< pr(A= a|X)< 1 for
all X,a. Under this assumption, the observed den-
sity f(Y |X,A= a) equals the density of the poten-
tial outcome f(Y a|X). Thus, one can use standard
approaches (e.g., regression of Y on X and A) to
estimate the effect of A on Y .
4.2 Stratification on Expected Auxiliaries
For stratification on expected auxiliary variables
(Hill, Waldfogel and Brooks-Gunn, 2002), identifi-
cation and estimation are somewhat more compli-
cated. The simplest method of estimation involves
two steps: estimating the expected auxiliary µa(X),
and estimation of effects by level of this expected
auxiliary. One can estimate the expected auxiliary
under ignorable treatment assignment [here
f(A|X,S) = f(A|X)] (Rosenbaum and Rubin, 1983)
using standard methods. For example, one can regress
S on X for subjects with A= a, then compute the
expected value as µˆa(X) based on the estimated re-
gression coefficients. Alternatively, one can regress S
on X and A, then estimate µˆa(X) as E(S|X,A= a),
using, for each subject, his or her observed X and
the desired treatment level a for all subjects; here,
one may choose to include interactions between A
and X as appropriate.
Under ignorable treatment assignment for the out-
come Y , one can again use standard methods to es-
timate the effect of treatment for a group classified
by µˆa(X). For example, one can fit a regression
E{Y |µˆa(X),A}
(3)
= β0 + µˆ
a(X)βµˆ +AβA + µˆ
a(X)AβµˆA;
here, the effect of treatment E{Y 1|µˆa(X)}−E{Y 0|
µˆa(X)} for subjects with expected auxiliary µˆa(X)
is βA+ µˆ
a(X)βµˆa. These plug-in type estimates are,
in general, consistent for the true parameters βA
and βµa in the corresponding regression on the true
scores µa(X) but will typically be biased in small
samples; this bias results from the fact that the es-
timate µˆa is a mismeasured version on the true ex-
pected auxiliary µa. It is of some interest to develop
unbiased estimators of these effects. Although we
are unaware of any such work in this setting, such
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work has been done with other generated regressors
(Pagan, 1984).
It is tempting to extrapolate the regression effect
and interpret βA + βµa as the effect for a subgroup
in which all subjects will develop ESRD if treated
aggressively, or as the effect for the group of sub-
jects who will develop ESRD if treated aggressively.
These interpretations are flawed. For the former,
there may be no subgroups identifiable on the basis
of pretreatment covariates in which all subjects will
develop ESRD, and so the parameter is not mean-
ingful. For the latter, additional assumptions may
be required for this interpretation to hold, as has
been discussed in a related context (Joffe, Ten Have
and Brensinger, 2003).
4.3 Stratification on Observed Auxiliaries
We are unaware of previous work on estimation of
parameters in models stratifying on observed auxil-
iary variables. Whereas the previous estimands al-
lowed nonparametric identification under ignorabil-
ity assumptions, estimation of these parameters will
require additional assumptions. We sketch one ap-
proach to estimation below; because of the relation
between observed auxiliary stratification and single
potential stratification and PS (Section 3.3), esti-
mation may also be based on estimating principal-
strata specific effects as described in the next subsec-
tion, then marginalizing over the unobserved auxil-
iary outcomes S¬a.
We consider estimation based on the following
idea, similar to G-estimation in structural nested
models (Robins, 1992; Robins et al., 1992; Robins,
1994). Estimation will require ignorability assump-
tions, as above. Suppose our outcome Y is continu-
ous; Y could be the logarithm of a failure-time (e.g.,
time of breast cancer mortality). We first propose a
model for the effect of treatment, for example,
E(Y 0|X,A,S)
(4)
=E(Y |X,A,S)−A(1− S)Ψ0 −ASΨ1.
Here, the realized effect of treatment for the sub-
group of subjects who received treatment and de-
veloped ESRD is Ψ1, and the realized effect for the
subgroup which received treatment but did not de-
velop ESRD is Ψ0. We have assumed that these ef-
fects do not vary with covariates X .
Under ignorability, Y 0 is independent of A given
X . Let Y 0(Ψ) = Y −A(1 − S)Ψ0 −ASΨ1; Y
0(Ψ)
may be computed from observed quantities and pu-
tative values for the causal parameters Ψ. Based
on the nonidentifiable assumption that treatment
effects are the same for all subjects with common
values of A and S, Y 0(Ψ) may be viewed heuristi-
cally as the potential outcome Y 0 if causal theories
represented by {Ψ0,Ψ1} are true. If the putative
value of the causal parameter Ψ is true, Y 0(Ψ) will
be independent of A given X . Estimation may be
based on testing this independence for an assumed
value of the causal parameter Ψ. Because Ψ is a
vector of dimension 2, estimation using scalar es-
timating equations will require either restriction of
the unknown parameter Ψ or a vector of estimating
equations of the same dimension as Ψ.
In some cases, one might assume that either Ψ0
or Ψ1 is 0. In the HIP study, it might be reason-
able to assume that screening affects breast cancer
mortality only for screened subjects diagnosed with
breast cancer, or, further, only for screened subjects
whose cancer was detected due to the screen (i.e.,
for subjects for whom S = 1,A= 1), and so Ψ0 = 0.
For binary A,
∑
i
(A− p)g{Y 0(Ψ),X}= 0(5)
provides valid estimating equations under the model
assumptions and ignorability, where p≡ pr(A= 1|X)
and g(·) is a known function of its arguments. The
optimal function g(·) is a sometimes complex func-
tion of the joint density of the observables and po-
tential outcomes (Joffe and Brensinger, 2003; Robins,
1992; Robins et al., 1992). Efficiency, but not con-
sistency, depends on choosing this optimal function.
Suppose that the “error” terms ε= Y 0 − E(Y 0|X)
are normal, independent, identically distributed ran-
dom variables and that S1 is unrelated to Y 0 [i.e.,
f(Y 0|X,A,S1) = f(Y 0|X)]. The optimal function is
then g{Y 0(Ψ),X} = ε(Ψ)E(S|X,A = 1), where
ε(Ψ) = Y 0(Ψ)−E{Y 0(Ψ)|X} (Joffe and Brensinger,
2003); the use of ε(Ψ) is similar to Rosenbaum’s
(2002) use of such residuals in randomization-based
inference. The estimated probability of treatment
may be substituted for the typically unknown true
p. The asymptotic variance of the resulting estima-
tor may be derived using a sandwich-type formula
(Robins, 1992; Robins et al., 1992).
If one is unable to restrict the parameter Ψ based
on subject-matter considerations, one must use a
vector of estimating equations. Here, we will require
vector functions g{Y (Ψ),X}. Under the above nor-
mality and homoscedasticity assumptions and under
the assumption that f(Y 0|X,A,S1) = f(Y 0|X), the
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optimal function is the vector function g{Y 0(Ψ),X}=
ε(Ψ){1−E(S|X,A= 1),E(S|X,A= 1)}T . g{Y 0(Ψ),
X} must have the same rank as the dimension of Ψ;
thus, if the covariate does not predict the auxiliary
outcome among the treated, there will be no ability
to estimate the vector Ψ. Under our assumptions
of equal effect across strata of X , the effect of A
on Y in any stratum of X is Ψ0{1 − E(S|X,A =
1)}+Ψ1E(S|X,A= 1), each term corresponding to
part of the vector function g{Y 0(Ψ),X}.
The approach taken above is semiparametric; that
is, consistency of the estimators of the parameters of
interest Ψ does not depend on parametric assump-
tions about the distribution of ε or the association of
X or S with Y 0. The methods presented above are
valid for structural distribution models, which map
percentiles in the distribution of Y 1 to percentiles in
the distribution of Y 0 in defined subgroups. In con-
trast, the weaker structural mean models only map
the mean of Y 1 to the mean of Y 0 [as in the for-
mulation in (4)]. Consequently, there are fewer valid
choices of the function g(·) for use in estimation [i.e.,
the function g(·) must be linear in Y 0(Ψ)] (Robins,
Rotnitzky and Scharfstein, 2000).
With binary outcomes, mean models are required.
Structural mean models using the identity link do
not restrict subgroup-specific means to the permissi-
ble range. With the usual logit link, semiparametric
models may be formulated, but consistent semipara-
metric estimators are not generally available (Robins,
Rotnitzky and Scharfstein, 2000; Robins and Rot-
nitzky, 2004). Extensions to binary outcomes whose
consistency depends on parametric assumptions are
available (Robins and Rotnitzky, 2004; Vansteelandt
and Goetghebeur, 2003).
4.4 Principal Stratification
Because the principal strata of many subjects are
not determined by the usual combination of data
and assumptions, inference for PS estimands will be
more dependent on assumptions and complicated.
The observed density of the main and auxiliary out-
comes may be expressed in terms of the unobserved
potential auxiliary outcomes SA as follows:
f(Y,S|A= a,X)
= f(Y |S,A= a,X)f(S|A= a,X)
=
∑
s¬a
f(Y |S,S¬a = s¬a,A= a,X)
· f(Sa, S¬a = s¬a|A= a,X)(6)
=
∑
s¬a
f(Y |S,S¬a = s¬a,A= a,X)
· f(S¬a = s¬a|S,A= a,X)
· f(S|A= a,X).
Under ignorability, the components of the right-hand
side of (6) are equivalent to models for the potential
main and auxiliary potential outcomes, f(Y |S,S¬a,
A = a,X) = f(Y a|S,X) and f(S,S¬a|A = a,X) =
f(S|X). Thus, parametrizing the models for the ob-
servables can lead to a likelihood for the causal quan-
tities of interest.
This likelihood is generally overparametrized. Sup-
pose that both S and A are scalar and binary. Then,
there are six unknown observed densities for each
level of covariates X : two for f(S|A = a,X) (one
for each level of A), and four for f(Y |S,A = a,X)
(one for each level of A and S). However, there are
eleven densities for the causal parameters in (6):
three for f(S|X) (there are four levels of S, but the
probabilities sum to 1), and eight for f(Y a|X,S)
(two levels of a × two levels of S× two levels of
S¬A). Thus, identification of causal effects will re-
quire further restrictions on the parameters. Before
proceeding to discuss such restrictions, we note that
there are (at least) two approaches which do not re-
quire identification: a Bayesian approach, in which
prior information is combined with the likelihood
to produce a posterior (Imbens and Rubin, 1997),
and approaches which derive bounds on causal ef-
fects (Balke and Pearl, 1997; Manski, 1990; Robins,
1989; Rubin, 2004; Zhang and Rubin, 2003; Cheng
and Small, 2006).
There are several forms of restrictions that can
be applied. These include restrictions on the joint
distribution of the potential auxiliary outcomes S
(i.e., on the principal strata), and restrictions on
the marginal distributions of the potential main out-
comes Y a.
One type of restriction on the auxiliary outcome
occurs when some level of the auxiliary outcome is
impossible under some treatment level a. Consider
first randomized trials with noncompliance, one area
in which the ideas of PS have been applied fre-
quently (Angrist, Imbens and Rubin, 1996; Baker
and Lindeman, 1994). In one view of these studies
(Imbens and Rubin, 1997), one may view random-
ization, the controlled factor, as the treatment A
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whose effect one is interested in estimating, and the
level of exposure to the experimental therapy S as
the auxiliary variable. One may be interested in the
effects of randomization for different classes of sub-
jects defined by the set of behaviors S = {S0, S1}
they would follow under different treatment assign-
ments. In some randomized trials, subjects assigned
the control treatment (A = 0) have no access to
the experimental therapy (S = 1); this may be com-
mon with investigational therapies not available out-
side of the trial. In this case, there are two rather
than four principal strata S : {S0, S1}= (0,1) (com-
pliers) and {S0, S1} = (0,0) (never-takers). In the
HIP Study, it may be reasonable (under the con-
ditions of the study in the 1960s) to reason that
subjects not assigned to screening (A = 0) could
not have received mammograms and so could not
have been diagnosed as a result of mammography
(S = 1). In these cases, the principal stratum of
the treated subjects is known; since S0 = 0, know-
ing the observed outcome S = S1 in a treated sub-
ject fully identifies S. Further, under ignorability,
the proportion of subjects in each principal stratum
pr(S|X) is identified. Under ignorability, the densi-
ties f(Y 1|X,S0, S1 = s) are identified as f(Y |X,S =
s,A= 1), but the densities f(Y 0|X,S,A= 0) are not
identified, and so the stratum-specific causal effects
are not identified without further assumptions.
A more general form of restriction on the potential
auxiliary outcomes consists of monotonicity restric-
tions, which have been adduced in a variety of set-
tings (Efron and Feldman, 1991; Gilbert, Bosch and
Hudgens, 2003; Angrist, Imbens and Rubin, 1996).
For any two ordered levels of treatment a, a′, a′ >
a, strict monotonicity states that Sa
′
≥ Sa for all
subjects (or, alternatively, that Sa
′
≤ Sa). Mono-
tonicity identifies the principal stratum of some sub-
jects. For binary S, monotonicity and ignorability
together permit identification of the proportion of
subjects in each principal stratum. In the HIP study,
if S is cancer diagnosis, one might assume that, if
a cancer were detected in an unscreened subject,
it also would have been detected had the subject
been screened (i.e., S1 >S0). This assumption may
be incorrect; for example, a woman who has been
screened and who was told that she had no cancer
may become less suspicious of cancer later, and so
screening might sometimes lead to a missed diagno-
sis of cancer.
None of these monotonicity assumptions, even in
conjunction with ignorability, is sufficient to identify
stratum-specific treatment effects. Such identifica-
tion typically requires assumptions about the out-
come distributions f(Y a|X,S). We outline several
such assumptions.
One strict set of assumptions is that treatment has
no effect on the outcome Y for some subsets of the
data defined by S. In randomized trials, it is com-
mon (Mark and Robins, 1993a; Sommer and Zeger,
1991) to assume that randomization has no effect
for those subjects for whom treatment has no effect
on S [i.e., Y a = Y a
′
if Sa = Sa
′
, or f(Y a|X,S) =
f(Y a
′
|X,S) if Sa = Sa
′
, a weaker assumption]; this
assumption is known as an exclusion restriction in
the econometrics literature (Angrist, Imbens and
Rubin, 1996). In studies of breast cancer screening
(e.g., HIP), one might assume that screening has
no effect among subjects whose tumors were not
detected through screening (i.e., for subjects with
S1 = 0, S0 = 0 where S = 1 if a subject has a screen-
detected tumor, 0 otherwise). In both of these ex-
amples, these restrictions, together with the mono-
tonicity restrictions and ignorability, are sufficient to
identify the causal effects [and, in fact, the marginal
densities f(Y a|X,S)] in the single principal stratum
in which treatment effects are not assumed to be
0. To see this, note that the marginal density of
the outcome may be written f(Y a|X) =
∑
s pr(S =
s)f(Y a|X,S = s); under our assumptions, pr(S = s)
is known for all s, and f(Y a|X,S = s) is identified as
either f(Y a|X,S,A= a) or f(Y a|X,S,A= 1− a) in
the principal strata in which treatment has no effect.
Further, the marginal densities f(Y a|X) are identi-
fied from the data under ignorability. This leaves one
unknown quantity f(Y a|X,S = s) for the principal
stratum in which the effect is not assumed to be
zero; we then solve f(Y a|X) =
∑
s pr(S = s)f(Y
a|
X,S = s) to find this unknown density.
When these assumptions are not reasonable, the
principal stratum-specific effects are not identified
without other assumptions. These assumptions can
take several forms: assumptions about how differ-
ent principal strata are from each other with re-
spect to the potential outcomes, assumptions about
the distribution of potential outcomes within princi-
pal strata, and assumptions about the associations
of covariates X with the potential outcomes within
principal strata.
Assumptions about the differences between princi-
pal strata may involve specifying E(Y 0|X,S = s)−
E(Y 0|X,S = s′) for some s, s′, s 6= s′; such assump-
tions are also sometimes framed in terms of the de-
gree of dependence of S1−A on Y 0 in models for
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pr(S1−A|X,S,A,Y 0). Such assumptions allow one
to avoid parametric assumptions about error distri-
butions. It is fairly difficult to have precise quantita-
tive knowledge about the degree of this dependency.
One way to deal with such uncertainty is to perform
a sensitivity analysis, in which one varies the sensi-
tivity parameter(s) over a plausible range (Gilbert,
Bosch and Hudgens, 2003); another way is to put
a prior distribution on the dependency parameter,
as done in various Bayesian analyses (Imbens and
Rubin, 1997).
Assumptions about the distribution of outcomes
Y a within a principal stratum are sometimes made
in both Bayesian and frequentist inference. Most of-
ten, f(Y a|S) is assumed to be normal with unknown
mean and variance (Imbens and Rubin, 1997); we
will consider likelihood-based inference under this
assumption. With these assumptions, identification
results from the identifiability of mixtures of cer-
tain parametric families of distributions (Teicher,
1963). For example, consider a model with two prin-
cipal strata, never-takers and compliers, for which
no exclusion restriction is assumed but the densi-
ties f(Y a|S) are assumed to be normal. Identifia-
bility of f{Y 0|S = (0,1)} and f{Y 0|S = (0,0)} re-
sults from the fact that f(Y |A= 0) is a mixture of
its two component normal distributions, and the pa-
rameters of a mixture of two normals are identifiable
(Teicher, 1963). In order to identify which mixture
component represents f{Y 0|S = (0,1)} and which
represents f{Y 0|S = (0,0)}, it is required that the
proportion of compliers not equal 0.5. Identification
based on parametric assumptions about the distri-
butions of outcomes f(Y a|S) may not be robust to
changes in parametric assumptions, as with selec-
tion models (Copas and Li, 1997).
Finally, one can make assumptions about the asso-
ciations of covariates X with the potential outcomes
within principal strata. For example, one might as-
sume that principal stratum-specific effects are con-
stant across covariates X [e.g., E(Y 1−Y 0|X = x,S) =
E(Y 1−Y 0|X = x′, S), for all x,x′]; this assumption
parallels assumptions we made for structural nested
models that effects conditional on observed auxil-
iaries do not vary with X . One might also assume
that the association of the covariates with poten-
tial outcomes has a particular parametric form [e.g.,
E(Y a|X,S) = q(S) +Xβ].
5. A SMALL SIMULATION EXPERIMENT
In this section, we report results of a small simula-
tion study to examine the performance of certain PS
and observed auxiliary stratification estimators. We
consider a continuous outcome Y , one binary covari-
ate X , and four settings (two sets of expected val-
ues for outcomes within the A,X,S strata and two
distributions of outcomes within the A,X,S strata
for each set of expected values). For the four set-
tings, the expected values of Y within the A,X,S
strata are shown in Table 3 along with the para-
metric distribution within the A,X,S strata. We
label the principal strata S by (S0 = 0, S1 = 0) =
immune (I), (S0 = 1, S1 = 0) = treatment protective
(TP), (S0 = 0, S1 = 1) = treatment harmful (TH) and
(S0 = 1, S1 = 1) = doomed (D) (Greenland and Robins,
1986). For all settings, the standard deviation of
Y within each A,X,S stratum is 1; E(Y |A,X =
1, S)− E(Y |A,X = 0, S) = 0.5 for all A,S, so that
the principal stratum-specific effects are constant
across the covariate X ; pr(S = I) = 0.25, pr(S =
TP) = 0.4, pr(S =TH) = 0.05 and pr(S =D) = 0.3;
and pr(X = 1|S = I) = 0.5, pr(X = 1|S =TP) = 0.75,
pr(X = 1|S = TH) = 0.25 and pr(X = 1|S = D) =
0.5. The sample size is 5000 for each setting and the
probability of being randomly assigned treatment
(A= 1) is 0.5.
We consider two PS estimators and one observed
auxiliary stratification estimator. The PS estimators
assume normal outcomes within each A,X,S stra-
tum. This assumption is satisfied for settings I(A)
and II(A) and violated for settings I(B) and II(B).
The PS estimators furthermore make the correct as-
sumption that E(Y |A,X = 1, S)−E(Y |A,X = 0, S)
is the same for all A,S. The first PS estimator we
consider does not put any constraints on E(Y |
A,X,S). The second estimator constrains the av-
erage effect of treatment in the immune principal
stratum given a value of X[E(Y |A = 1,X,S = I)−
E(Y |A= 0,X,S = I)] to be equal to the average ef-
fect of treatment in the treatment protective prin-
cipal stratum given the same value of X and con-
strains the average effect of treatment in the treat-
ment harmful principal stratum given a value of X
to be equal to the average effect of treatment in
the doomed principal stratum given the same value
of X . The constraint made by the second PS es-
timator is correct for settings I(A) and I(B) but
is incorrect for settings II(A) and II(B). We used
the EM algorithm to implement the PS estimators
and used the true parameters as the starting values.
The observed auxiliary stratification estimator is
based on model (4) and uses the function
g{Y 0(Ψ),X}= ε(Ψ){1−E(S|X,A= 1),E(S|X,A=
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1)}T discussed in Section 4.3. Model (4) is correct
for settings I(A) and I(B) but is incorrect for set-
tings II(A) and II(B); in settings II(A) and II(B),
E(Y |X,A,S) − E(Y 0|X,A,S) varies with X . For
the observed auxiliary stratification estimator, we
used the computational procedure for weighted
G-estimation described in Ten Have, Elliott, Joffe,
Zanutto and Datto (2004) using the true values as
the starting values. R code for the simulations and
analysis and an example dataset are available at
www. cceb.upenn.edu/ faculty/?id= 157 .
Table 4 displays the means and standard devia-
tions of the estimators for 500 simulations of each
setting. In setting I(A), the assumptions made by all
three estimators are correct. All the estimators pro-
vide approximately unbiased estimates of their cor-
responding estimands. The PS II estimator that con-
strains certain average effects of treatment within
principal stratum to be equal is the most efficient
estimator. The PS II estimator and the observed
auxiliary stratification estimator make similar as-
sumptions, but the additional parametric assump-
tions made by the PS II estimator make it consid-
erably more efficient. In setting I(B), the assump-
tions made by the observed auxiliary stratification
estimator continue to hold but the parametric as-
sumptions made by the PS estimators are false. The
observed auxiliary stratification estimator performs
similarly in setting I(B) as it did in setting I(A)—it
is approximately unbiased and has a similar vari-
ance. In contrast, the PS estimators exhibit consid-
erable bias for some of their estimands in setting
I(B). The PS I estimator has a particularly large
bias for the average effects of treatment in the im-
mune and doomed principal strata. In settings II(A)
and II(B), the assumption made by the observed
auxiliary stratification estimator that treatment ef-
fects conditional on observed auxiliaries do not vary
with the covariate X is false. In the “Truth” col-
umn for Ψ0 and Ψ1, we list the average realized
effects of treatment for subjects with S1 = 0 and
S1 = 1, respectively. The observed auxiliary stratifi-
cation estimator of Ψ0 for settings II(A) and II(B)
does not show much bias but the estimator of Ψ1
shows considerable bias. For the PS estimators, the
assumptions made by PS estimator I are true in set-
ting II(A) and false in setting II(B), and the as-
sumptions made by PS estimator II are false in both
settings. As in settings I(A) and I(B), PS estimator
I is approximately unbiased when its parametric as-
sumptions hold [setting II(A)] but is considerably
biased for some estimands when its parametric as-
sumptions do not hold [setting II(B)]. For setting
II(A), PS estimator II provides slightly biased but
low variance estimates of the average effects of treat-
ment across the immune and treatment protective
strata and the average effect of treatment across
the treatment harmful and doomed strata (the value
listed in the Truth column for the PS II estimator
for immune=treatment protective is the average ef-
fect of treatment among subjects with S1 = 0 and
for treatment harmful=doomed is the average effect
of treatment among subjects with S1 = 1). For set-
ting II(B), PS estimator II’s estimate of the average
effect of treatment across the treatment harmful and
doomed strata is substantially biased.
In summary, all of the estimators are somewhat
sensitive to their assumptions. The PS I estima-
tor makes no assumption about how the average ef-
fects within a principal stratum [E(Y |A= 1,X,S)−
E(Y |A= 0,X,S)] compare between principal strata,
but is sensitive to its parametric assumptions. The
PS II estimator and observed auxiliary stratification
Table 3
Parameter values for simulation study
Setting I(A) I(B) II(A) II(B)
E(Y |A= 1,X = 0, S = immune) 2 2 2 2
E(Y |A= 0,X = 0, S = immune) 1 1 1 1
E(Y |A= 1,X = 0, S = treatment protective) 2.5 2.5 2.5 2.5
E(Y |A= 0,X = 0, S = treatment protective) 1.5 1.5 1 1
E(Y |A= 1,X = 0, S = treatment harmful) 1.25 1.25 1.25 1.25
E(Y |A= 0,X = 0, S = treatment harmful) 0.75 0.75 0.75 0.75
E(Y |A= 1,X = 0, S = doomed) 1.75 1.75 2.25 2.25
E(Y |A= 0,X = 0, S = doomed) 1.25 1.25 1.25 1.25
Distribution within each A,X,S0, S1 stratum Normal Gamma Normal Gamma
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Table 4
Simulation study results
Settings I(A) and I(B)
Setting I(A) Setting I(B)
Estimator Truth Mean SD Truth Mean SD
Principal stratification estimator I average effects of treatment
Immune 1 0.97 0.23 1 0.11 0.14
Treatment protective 1 1.00 0.13 1 0.82 0.05
Treatment harmful 0.5 0.54 0.48 0.5 0.68 0.06
Doomed 0.5 0.51 0.19 0.5 1.36 0.10
Principal stratification estimator II average effects of treatment
Immune=treatment protective 1 1.00 0.03 1 0.78 0.14
Treatment harmful=doomed 0.5 0.50 0.04 0.5 0.60 0.08
Observed auxiliary stratification
Ψ0 1 1.00 0.12 1 1.00 0.12
Ψ1 0.5 0.50 0.21 0.5 0.50 0.21
Settings II(A) and II(B)
Setting II(A) Setting II(B)
Estimator Truth Mean SD Truth Mean SD
Principal stratification estimator I average effects of treatment
Immune 1 0.98 0.22 1 0.00 0.14
Treatment protective 1.5 1.52 0.14 1.5 1.91 0.06
Treatment harmful 0.5 0.60 0.54 0.5 1.16 0.08
Doomed 1 0.96 0.21 1 0.43 0.08
Principal stratification estimator II average effects of treatment
Immune=treatment protective 1.42 1.33 0.03 1.42 1.63 0.04
Treatment harmful=doomed 0.93 0.88 0.04 0.93 −0.01 0.07
Observed auxiliary stratification
Ψ0 1.42 1.51 0.12 1.42 1.52 0.13
Ψ1 0.93 0.56 0.23 0.93 0.53 0.23
estimator both put the same constraints on how the
average effects within principal strata compare, and
both estimators are sensitive to these constraints
holding. The PS II estimator was considerably more
efficient than the observed auxiliary stratification es-
timator when its parametric assumptions held, but
showed considerable bias for some estimands when
its parametric assumptions did not hold. We also
performed the same set of simulations for a sam-
ple size of 500; the results are not shown but are
available from the authors. The performance of the
estimators and the way in which the estimators com-
pare were similar to what is shown in Table 3 for
the larger sample size of 5000. Some notable fea-
tures of the simulations for the smaller sample size
of 500 were: (1) in a very small proportion of simu-
lations (approximately 0.005%), the observed auxil-
iary stratification estimator produced estimates that
were very large in absolute value (more than 100
times the true value); (2) in a very small propor-
tion of simulations (approximately 0.1%), the PS I
estimator did not converge; and (3) the PS estima-
tors exhibited a small amount of bias (a maximum
of about 0.1) for some estimands even when their
parametric assumptions held.
For the settings considered in Table 3 (with a sam-
ple size of 5000), we also computed the expected
auxiliary stratification estimator based on model (3).
The means of the estimates of βA+βµA were −3.00,
−2.99, −2.18 and−2.19 for settings I(A), I(B), II(A)
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and II(B), respectively. These mean estimates are
not close to the effect of treatment for the sub-
group of subjects with S1 = 1. These results illus-
trate the point mentioned at the end of Section 4.2
that the expected auxiliary stratification estimates
cannot necessarily be extrapolated to reliably esti-
mate the effect of treatment for the subgroup of sub-
jects who will have a certain value of the auxiliary
variable if treated.
6. ANALYSIS OF THE HIP DATA
The Health Insurance Plan (HIP) Study (Shapiro
et al., 1988) was a randomized trial of screening for
breast cancer, in which more than 60,000 women
aged 40–64 at the start were randomized into two
groups. In the treatment arm, women were offered
screening examinations, consisting of mammogra-
phy and clinical exam, to be provided in an initial
visit and three annual follow-up visits. About one-
third of women in the treatment arm refused screen-
ing; some of the others did not receive some of the
follow-up exams; this information is also recorded.
Women in the control group received usual care.
The study recorded information on date of death
for women who died; cause of death was classified
as being due to breast cancer or not. The study also
recorded information on whether and when a par-
ticipant was diagnosed with breast cancer, and if
so, whether the cancer was detected by one of the
screening exams in the study.
We analyzed the HIP data using G-estimation of
structural models. For these analyses, our outcome
Y is the natural logarithm of our failure-time, death
from breast cancer. Because most subjects in the
study do not experience the outcome of interest be-
fore the end of follow-up, the outcome is said to be
censored.
We consider several choices of the auxiliary out-
come S. For the first, S = 1 if a subject receives a
screen, 0 otherwise; for the second, S = 1 if a subject
is screened and diagnosed with breast cancer, 0 oth-
erwise; for the third, S = 1 if a subject is diagnosed
with breast cancer and that cancer was detected by
the screen, 0 otherwise. Here, the treatment of in-
terest A is (randomized) assignment to the screen-
ing arm. We assume that assignment to the screen-
ing arm has no effect on the outcome unless a sub-
ject actually is screened and is diagnosed (for the
third choice, diagnosed based on the screen), and so
Ψ0 = 0. Because of censoring, we use as our function
g{Y 0(Ψ),X}=∆(Ψ), where ∆(Ψ)≡ I{Y (Ψ)<C(Ψ)},
C(Ψ) =min{C,C exp(Ψ)} (for binaryA,S, and scalar
Ψ), and C denotes a subject’s potential censoring
time (here ten years). Other references (Joffe, 2001;
Mark and Robins, 1993b; Robins, 1992) discuss the
more general approach to dealing with administra-
tive or generalized type I censoring. Joffe (1994) pro-
vides fuller justification for use of this particular
function. To deal with competing risks, we weight
the estimating functions for subjects not censored
by competing risks by the inverse of their probabil-
ity of being uncensored at the end of their follow-
up; Robins et al. (1992) provide more details. We
consider subjects who died of other causes as cen-
sored by a competing risk, although this is some-
what problematic (Kalbfleisch and Prentice, 2002).
For our analysis, we consider the first ten years
of follow-up for each subject. In this period, 1259
subjects were diagnosed with breast cancer (626 of
these were in the screening arm). There were 340
deaths attributed to breast cancer: 193 in the control
arm and 147 in the screening arm. Among the 441
cancers diagnosed among subjects who received at
least one screen, 132 cancers were detected by the
screen; among the 100 screened breast cancer cases
who died of breast cancer, 27 had been detected by
the screen.
We applied the modified G-estimation approach
to these data. Figure 2 plots the Z-test statistics
for each choice of S against Ψ1. The test statis-
tics for Ψ1 = 0 are identical [Z = −2.39, p = 0.017
(2-sided)]. When S denotes diagnosis of breast can-
cer among screened subjects, the absolute value of
the statistic is minimized around Ψ1 = −0.20, and
the 95% confidence interval is (−0.49,−0.06); this
means that screening lengthens the time to breast
cancer mortality by a factor of [exp{−(−0.2)}− 1] ∗
100% = 22% (6%,63%) among screened subjects di-
agnosed with breast cancer. We obtain identical re-
sults when S denotes receiving a screen, and so the
model estimates may also be interpreted as the effect
of screening on screened subjects. This is so because,
for any given value of Ψ, g{Y 0(Ψ),X} = ∆(Ψ) is
the same whether S denotes screening or cancer
diagnosis following screening. Because screening is
unavailable in the control arm, these estimates are
also estimates of complier average causal effects (Im-
bens and Rubin, 1997). When S denotes breast can-
cer diagnosis as the result of a screen, the corre-
sponding point estimate (95% confidence interval) is
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−0.76 (−1.15,−0.27); the corresponding lengthen-
ing is 114% (31%, 216%). Thus, the effect of screen-
ing among screened subjects diagnosed with breast
cancer is less than the effect on the subset of these
subjects whose diagnosis was a result of the screen-
ing, as would be expected.
7. UTILITY OF VARIOUS APPROACHES
Causal modeling has multiple purposes. These
include assisting in making decisions about possible
interventions, predicting the results of those inter-
ventions, and better understanding of the processes
leading to the outcome(s) under study. We consider
the approaches sketched above in terms of their util-
ity for these purposes, as well as generalization of
study results.
7.1 Making Decisions
Making decisions about possible interventions and
predicting the results of those interventions are closely
linked. Normally, one would want to choose, for any
individual, the treatment that leads to the best pos-
sible expected result, however that is defined. This
decision must be made on the basis of information
available at the time of the decision; for point expo-
sures, that means only baseline covariates may be
used to predict outcomes under a given treatment
and so guide treatment decisions.
We formalize this within a decision-theoretic frame-
work. Let Li(S
a, Y a;a) denote an individual’s loss
function associated with decision a. The loss func-
tion may be associated with the subject’s principal
stratum, observed auxiliaries or outcomes, measured
pretreatment covariates, or other individual-specific
Fig. 2.
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factors. To formalize this idea, let Q denote a col-
lection of variables. We can write the expected loss
given Q as E{Li(S
a
i , Y
a
i , a)|Q}. Under the usual
decision-theoretic framework, a decision should de-
pend only on information available at the time of the
decision; further, if the decision is to be based only
on information available in the statistical models fit
to the data, we can condition only on measured base-
line covariates X . Under these constraints, decisions
should be based only on comparisons of E{Li(S
a
i ,
Y ai , a)|X} for different treatments a, and so depend
on the joint density of the potential outcomes
f(S,Y |X) only through the marginal densities
f(Sa, Y a|X) = f(Sa|X)f(Y a|Sa,X), where S ≡ {Sa},
a ∈A and A denotes the set of possible treatments
a. Thus, the optimal feasible decision based solely
on data available to the study will depend on the
marginal distributions f(Sa|X) and f(Y a|Sa,X),
both of which are estimable using conventional meth-
ods (the latter as described in Section 2.2); the use of
the factorization of the marginal density f(Sa, Y a)
for estimation will be particularly important when
Y a is undefined for some values of Sa (e.g., with
censoring by death). Relying solely on the marginal
density f(Y a|X) will be adequate for deciding among
treatments if the loss does not depend on Sa or if the
auxiliary variable is not affected by treatment and
the loss function may be written as the sum of sepa-
rate components associated with main and auxiliary
outcomes [i.e., if Li(S
a, Y a;a) = q1(S
a)+ q2(Y
a) for
some functions q1(·) and q2(·)]. If the loss is a func-
tion of Sa, none of the estimands discussed in Sec-
tion 3 is adequate by itself, as they focus only on
the density of Y a [some methods proposed in con-
junction with PS (Imbens and Rubin, 1997) yield
estimates of f(Sa|X) and so potentially could be
used to estimate f(Sa, Y a)]. In the nephrology ex-
ample, the auxiliary outcome, ESRD, is a condition
with severe and life-disrupting consequences (requir-
ing dialysis or transplant) which would normally in-
fluence the loss function.
Suppose that the loss is not a function of Sa. In
the cancer screening example, it is arguable that
the benefits of screening should be assessed solely
in terms of mortality Y a, even though there are
costs that are associated with cancer diagnosis, in-
cluding the financial costs of administering screen-
ing exams, patient inconvenience, and the costs of
falsely diagnosing a subject as having cancer who
actually does not, which can both lead to unneces-
sary surgical procedures and have adverse psycho-
logical impact (Brett, Bankhead, Henderson, Wat-
son and Austoker, 2005; Barratt, Irwig, Glasziou,
Salkeld and Houssami, 2002). If the loss is a func-
tion of Y a alone, optimal decisions should be based
on f(Y a|X); that is, we should seek to minimize
E{Li(S
a, Y a, a)|X} =E{Li(Y
a, a)|X} =
∫
Y a Li(Y
a,
a)f(Y a|X)dY a. Suppose that, as is typical, Li(Y
a
i , a)
is a monotonic function of Y ai for all subjects (e.g.,
mortality is never a desired outcome); suppose fur-
ther that Li(Y
a
i , a) does not depend on a and so
Li(Y
a
i , a) = Li(Y
a′
i , a
′) for all a, a′ (e.g., the loss as-
sociated with mortality does not depend on whether
one had been screened). Then, the relative expected
loss for an individual under one treatment relative to
another can be assessed by comparing the densities
f(Y a|X) and f(Y a
′
|X).
Although these quantities may be evaluated from
a model which conditions on a post-treatment auxil-
iary, such evaluation will typically be more involved
than the simpler and more direct modeling of the
marginal densities f(Y a|X). Let Z denote a post-
treatment auxiliary; Z can be a principal stratum or
the single potential auxiliary Sa. We can compute
and estimate f(Y a|X,Z) using methods discussed
above (including the methods based on observed
auxiliary stratification; Section 4.3); nonetheless, to
make a decision, we must integrate out the auxiliary
Z, as it is unknown at the time a decision is be-
ing made. Thus, from models based on PS or single
potential auxiliaries, we can assess the loss by eval-
uating f(Y a|X) =
∑
z f(Y
a|X,Z = z)pr(Z = z|X);
these calculations are more involved than those based
on stratifications based on the observed covariates
X , where the most relevant comparison of densities
can be read simply (or directly) from a single re-
gression of Y on X and A. Further, the increased
number and complexity of the models required to
evaluate the desired quantities may lead to increased
likelihood of obtaining incorrect conclusions due to
model misspecification. If the sharp null hypothe-
sis of no effect is true, tests of the null using G-
estimation of parameters in structural nested mean
models will be (relatively) robust to model misspec-
ification in randomized trials, because they essen-
tially are based on intent-to-treatment tests of the
null (Robins, 1992).
Information on the expected value of post-treatment
auxiliaries more generally might be of use in mak-
ing decisions in situations in which decision mak-
ers had a better idea of the value of these post-
treatment auxiliaries than can be assessed from the
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data. This could happen if, for example, a new test
were developed that discriminates well between sub-
jects who will and will not develop the auxiliary out-
come. Then, effects for groups defined by an auxil-
iary variable might be used to infer the effects of
treatment for groups defined by this baseline vari-
able. Additionally, finding that effects of treatment
differ for subjects with different levels of the auxil-
iary variable could be a useful spur to find baseline
variables which predict the auxiliary variable well.
For making decisions, even the expected auxiliary
outcomes play no special role in principle. For this
purpose, covariates which strongly modify the ef-
fects of treatment (measured on a clinically relevant
scale) are of greatest value. Sometimes, the expected
auxiliary may be such an effect modifier; in the can-
cer screening example, it is plausible that the risk
of breast cancer would be an important modifier of
the benefit of screening, especially if the benefit is
assessed on the scale of difference in probability of
mortality if screened or not. Unfortunately, we can-
not evaluate this in the HIP study, which collected
little covariate information.
7.1.1 Treatments given over an extended period.
Where the treatment is actually applied over an ex-
tended period of time, estimands stratifying on post-
treatment auxiliaries may have more immediate rel-
evance for decision making. Suppose that the auxil-
iary variable is measured shortly after the initiation
of treatment. Suppose further that treatment never
changes over the course of follow-up and that the
effect of treatment on the ultimate outcome, mea-
sured at the end of a fixed follow-up period, is cumu-
lative (i.e., the effect of treatment given early during
follow-up on this outcome is in the same direction
as the effect of treatment later). Then, finding that
treatment is beneficial for some groups defined by
post-treatment variables and harmful for others will
lead to recommendations to discontinue treatment
for the group for whom treatment is harmful.
To illustrate and formalize this, consider elabo-
rating model (4) to model the effect of the different
components Ak of treatment received at different
times k, k = 1, . . . ,K. Let A˙≡ (
∑K
k=1Ak)/K be the
average value of treatment received during follow-
up. The model
Y 0 = Y − A˙(1− S)Ψ0 − A˙SΨ1(7)
is indistinguishable from model (4) when treatment
for all subjects remains constant over time; if the
model is correct and S is assessed early in follow-
up, one would then be justified in making treatment
decisions beyond k based on the value of S measured
by k. Such inference is, however, strongly dependent
on modeling assumptions. To see this, consider the
model
Y 0 = Y −A1(1− S)Ψ0 −A1SΨ1,(8)
which specifies that the only treatment which af-
fects the outcome is that received during the first
period. When treatment Ak remains constant over
time, this model is indistinguishable in the data
from model (7); nonetheless, one model will suggest
that treatment may be beneficial beyond k, whereas
the other will not.
7.2 Explanatory Analyses
Another possible use of analysis stratifying on post-
treatment auxiliaries is explanatory. In scientific work,
one typically wants to explain the data in ways which
will lead not only to an understanding of the data
themselves but also to generalization to other set-
tings (often beyond the sampling frame of the study).
In this section, we consider the utility of analysis
stratifying on post-treatment auxiliaries for such ex-
planation and contrast it with approaches which
concentrate on causal mechanism.
7.2.1 Two types of explanation: effect modifica-
tion vs. causal mechanism. Effects which vary by
post-treatment auxiliaries can be used to explain
observable differences in outcomes between groups
receiving different treatments (White and Goetghe-
beur, 1998). For example, in the HIP study, an ef-
fect of screening Ψ1 of −0.2 for screened subjects
diagnosed with breast cancer (or −0.76 for screened
subjects diagnosed due to the screen), together with
no screening effect in the remaining subjects, can
explain the differences in survival between the ran-
domized groups. We say that there is effect mea-
sure modification (Rothman and Greenland, 1998)
here by the post-treatment auxiliary (diagnosis af-
ter screen or diagnosis due to screen) because the
measure of treatment effect differs between the dif-
ferent groups defined by the auxiliary [i.e., Ψ1 6=Ψ0
in (4)]; this variation in effects can be used to ex-
plain the differences between the groups.
One might be tempted to conclude that cancer
diagnosis (or its correlates) participates in the pro-
cesses leading to improved survival and perhaps in-
teracts causally with the treatment of interest. Such
18 M. M. JOFFE, D. SMALL AND C.-Y. HSU
mechanistic inference will often be suggestive but
is fraught with pitfalls (Thompson, 1991). In par-
ticular, the concept of effect measure modification
(a.k.a. statistical interaction) differs from mechanis-
tic interaction in that effect measure modification
does not require that the modifier itself be a variable
which can be modified directly, whereas mechanistic
interaction requires the modifier to be the subject of
intervention. Thus, one need not speak of the causal
effect of an effect modifier.
Effect modification by post-treatment auxiliary vari-
ables provides less satisfactory and less satisfying
explanations of observed associations when divorced
from the concepts of causal mechanism and causal
intermediates. To see this, consider a scenario in
which the effect of aggressive blood pressure man-
agement on MI is greater for subjects who subse-
quently develop ESRD [e.g., |g{E(Y 1|A= 1, S = 1)}−
g{E(Y 0|A= 1, S = 1)}|> |g{E(Y 1|A= 1, S = 0)} −
g{E(Y 0|A= 1, S = 0)}| for some monotone link func-
tion g(·); typically g(y) is either y (the identity link,
leading to risk differences), ln(y) (the log link, lead-
ing to risk ratios) or logit(y) (the logit link, leading
to odds ratios)]. Contrast the following four state-
ments:
1. The effect of aggressive treatment of blood pres-
sure on MI is greater for people who subsequently
develop ESRD (observed auxiliary stratification),
with the effects in the different subgroups ex-
plaining the overall difference between subjects
treated aggressively and those not.
2. The effect of aggressive treatment of blood pres-
sure on MI is greatest for people who would de-
velop ESRD only if not treated aggressively (prin-
cipal stratification).
3. Aggressive treatment of blood pressure prevented
the development of ESRD in some subjects (one
principal stratum). This, in turn, prevented the
development of MI for some subjects. Thus, ESRD
mediated in part the effect of aggressive manage-
ment of blood pressure on MI.
4. Aggressive treatment of blood pressure prevents
the development of ESRD in some subjects. This,
in turn, prevents the development of MI for some
subjects. Thus, ESRD mediates in part the effect
of aggressive management of blood pressure on
MI.
The last two statements attempt to provide some
understanding of the causal mechanisms leading from
blood pressure treatment to MI; these are often con-
sidered in terms of direct and indirect effects (Pearl,
2001; Robins and Greenland, 1992; Robins, 1999).
The first two do not attempt such explanation. State-
ments 3 and 4 are identical except for the tense.
Statement 3 is an attempt to explain what has hap-
pened; statement 4 refers to more general causal pro-
cesses and in principle is an attempt to predict the
future and so is more ambitious.
In general, we prefer statements 3 and 4. State-
ments 1 and 2 are not, in general, useful for mak-
ing treatment decisions, and the quality of their ex-
planations of the data is poor. Where warranted
based on appropriate subject-matter considerations,
statements 3 and 4 provide informative explana-
tions. At the risk of generalizing beyond the data at
hand, statement 4 makes general statements about
causal processes which are then potentially testable
in other data. An important role of science is to
extrapolate from one’s data and make predictions
which may be testable in other data or designs; this
is most easily fostered by considering causal mech-
anisms. This important scientific goal is sometimes
fostered by considering effects of auxiliary variables
that are not under the direct control of the inves-
tigator in the given study; Rubin (2004) presents a
somewhat contrary view.
In the nephrology example, it is meaningful to
consider the effect of ESRD on MI; this accords
nicely with common usage. The effect can be ap-
proximated by comparing what would happen to
someone who has or develops ESRD with what would
have happened had that person received a trans-
plant from a genetically identical person (an iden-
tical twin or identical triplets) who did not have
ESRD. Even though this experiment could rarely, if
ever, be carried out, it provides a useful approach for
defining the effect in terms of a thought experiment.
DAGs provide a nice intuitive representation of di-
rect and indirect effects; the ideas of potential out-
comes and counterfactuals allow these ideas to be
made more precise. Figure 3 shows causal relation-
ships among the variables. In this graph, the path
A→ S→ Y represents the indirect effect of A on Y
(i.e., that part of the effect of A that is mediated by
the specified variable S; it is necessary to specify the
auxiliary variable(s) S to define what is meant by in-
direct and direct effects), and A→ Y represents the
direct effect of A on Y (i.e., that part of the effect
not mediated by S). Graphs like this are sometimes
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known as path diagrams and have been used to jus-
tify the use of linear models for multivariate normal
data (Pearl, 2000). The path-analytic approach suf-
fers from the lack of a nonparametric definition of
causal effects and generally unrealistic assumptions
of multivariate normality; further, it does not ex-
tend naturally to settings with interactions among
the variables or to nonlinear models.
The ideas of potential outcomes may be used to
define direct, indirect and joint effects of treatment.
Let Y a,s denote the (continuous) outcome one would
see for a given subject at level a of the main treat-
ment of interest (e.g., management of hypertension)
and level s of the auxiliary outcome (e.g., ESRD).
Underlying the notation is the assumption that the
auxiliary outcome is in some sense manipulable. The
notation has been used in conjunction with PS (An-
grist, Imbens and Rubin, 1996) as well as discussions
of direct and indirect effects.
The direct effect of the main treatment A con-
trolling for an auxiliary variable S may be defined
as the contrast of Y a
1,s and Y a
0,s for an individ-
ual or a group; that is, the direct effect contrasts
the outcome that would be seen under two different
levels of the primary treatment, physically manipu-
lating the auxiliary variable to a given level s. Direct
effects are not uniquely defined; there are separate
direct effects for each level of the auxiliary variable
s.
There are, in fact, two separate types of direct
effects (Pearl, 2001; Robins and Greenland, 1992;
Robins, 2003), depending on the nature of the ma-
nipulation of the auxiliary variable. If the auxiliary
variable is set to a prespecified level s, the resulting
contrasts are known as “controlled” direct effects.
If the auxiliary variable is set to the level it would
Fig. 3. A directed acyclic graph representing the relations
among the variables in the example of Section 7.2.
have reached at some reference level a∗ of the treat-
ment, the effects are known as “natural” direct ef-
fects; natural direct effects are contrasts of Y a
1,Sa
∗
and Y a
0,Sa
∗
, a∗ ∈ {a0, a1}. For a∗ = a0, the natural
direct effect is a contrast of the potential outcome
that would have been seen had the main treatment
been set to level a1 but the auxiliary variable set to
the level Sa
0
it would have taken had the subject
been given level a0 with the potential outcome that
would have been seen had the subject been given
level a0 of the main treatment.
Although there is no general definition of con-
trolled indirect effects, natural indirect effects are
nonparametrically defined as contrasts of Y a
∗,Sa
1
and Y a
∗,Sa
0
; that is, for a∗ = a0, the indirect effect
is a contrast of what would have happened had a
subject been given treatment a0 but had his or her
auxiliary variable set to the level Sa
1
it would have
attained had he or she been given a1 with what
would have happened had the subject been given
a0. Statements 3 and 4 above may be understood
as speaking about the natural indirect effects of ag-
gressive management of blood pressure.
7.2.2 Contrasting models for contrasting explana-
tions. We present here a simple semiparametric model
which allows us to contrast the ideas of mediation
with those presented previously, in particular, with
the modification of treatment effect by post-treatment
covariates, as in (4). We consider a continuous out-
come variable Y . A simple model for the joint effects
of hypertension management and ESRD is
Y a,s = Y 0,0 + aγ1 + sγ2 + asγ3.(9)
In this model, γ1 represents the controlled direct ef-
fect of aggressive treatment of blood pressure (hold-
ing S at 0), γ2 represents the effect of modification
of ESRD and γ3 represents an interaction between
ESRD and aggressive treatment of blood pressure.
Under an assumption of monotonicity of the effect
of treatment A on S (e.g., S1 ≤ S0), the parameter
γ ≡ {γ1, γ2, γ3} is related to the effects of aggressive
treatment of blood pressure on principal strata as
follows:
for subjects doomed to develop ESRD (S1 = S0 =
1), the effect of aggressive treatment (Y 1 −Y 0 =
Y 1,S
1
− Y 0,S
0
) is γ1 + γ3;
for subjects immune to ESRD (S1 = S0 = 0), the
effect of aggressive treatment is γ1;
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for subjects for whom treatment prevents ESRD,
the effect of aggressive treatment is γ1 − γ2.
In this model, statement 2 (now relating to a con-
tinuous cardiovascular outcome) that the beneficial
effect of aggressive treatment of blood pressure is
greatest for people who would develop ESRD only
if not treated aggressively is implied by γ2 > 0, γ3 >
−γ2 (assuming small values of Y are better out-
comes). Further, if γ2 > 0 and aggressive treatment
and ESRD do not interact in affecting the outcome
(i.e., γ3 = 0), then statement 2 is true, as is state-
ment 4.
Further, the effect of treatment among treated
subjects who do not develop ESRD is
E(Y 1|A= 1, S = 0)−E(Y 0|A= 1, S = 0)
=E(Y 1,S
1
− Y 0,S
0
|A= 1, S1 = 0)
=
∑
s
pr(S0 = s|A= 1, S1 = 0)
·E(Y 1,S
1
− Y 0,S
0
|A= 1, S1 = 0, S0 = s)
= γ1 − pr(S
0 = 1|S1 = 0)γ2,
and the effect of treatment among the treated who
develop ESRD is γ1 + γ3. Thus, Ψ0 in (4) equals
γ1 − pr(S
0 = 1|S1 = 0)γ2, and Ψ1 = γ1 + γ3.
In a randomized trial of A, the parameters in
model (9) are identified from the data under two
types of assumptions:
1. The assumption that the initial treatment A is
randomized, along with the modeling assumptions
inherent in (9) (Robins and Greenland, 1994; Ten
Have et al., 2004). In this approach, the modeling
assumptions are not fully testable, even in very large
studies. This approach is similar to that proposed
above for observed auxiliary stratification and un-
der some conditions is essentially identical. For G-
estimation, the approach requires the same number
of estimating equations as the number of free param-
eters. Under the above normality and homoscedas-
ticity assumptions and the assumption that f(Y 0,0|X,
A,S1) = f(Y 0,0|X), the optimal function is the vec-
tor function g{Y 0,0(γ),X}= ε(γ){1,E(S|X,A = 1)−
E(S|X,A = 0),E(S|X,A = 1)}T . We now require
the covariate vector to predict not only the level of
the auxiliary variable among the treated [as was true
for model (4)], but also to predict the effect of the
primary treatment on the auxiliary, and we require
the three elements {1,E(S|X,A = 1)−E(S|X,A=
0),E(S|X,A= 1)} to not be collinear; this often re-
quires at least two covariates. Restrictions on the
parameter space can result in a smaller vector of
estimating functions; typically, the restrictions are
either that there is no interaction between A and
S (i.e., γ3 = 0) (Robins and Greenland, 1994; Ten
Have et al., 2004), or that some parameters play no
role in explaining the data and so are not estimable.
To explain the latter, suppose that one level of a bi-
nary auxiliary variable S does not occur for some
level of treatment A; for example, pr(S = 1|A =
0) = 0; in the HIP study, this is true both when
S denotes screening and when S denotes diagnosis
due to screen. Under this condition, S =AS for all
subjects, and one cannot simultaneously estimate
both the main effect of S (γ2) and its interaction
with A (γ3) in (9). Under this model, for a binary
treatment and auxiliary variable, the effect of the
auxiliary treatment S (γ2) is the same as the ef-
fect of the main treatment A among treated sub-
jects with S = 1(Ψ1). Thus, the effect of assignment
to screening for screened women who are diagnosed
due to the screen [Ψ1 in (4)] might also be inter-
preted as the effect of diagnosis or early detection
by screen [γ2 in (9)], and the effect of assignment
to screen among subjects who received the screen
might also be interpreted as the effect of screen-
ing.
2. The assumptions above, plus the assumption
the assignment of the auxiliary variable S is ig-
norable; that is, pr(S|X,A,L,Y a,s) = pr(S|X,A,L),
where X refers to covariates measured at baseline
and L to covariates measured after baseline but be-
fore S (Robins and Greenland, 1992). Under the ad-
ditional but untestable ignorability assumption, the
structural model (9) is fully testable.
The DAG in Figure 3, which corresponds to a ran-
domized trial of the main treatment A, is consis-
tent with assumption 1 but not assumption 2. The
assumption of initial randomization is justified be-
cause there are no arrows into A; further, the arrow
from X to S is consistent with an association be-
tween X and S among treated subjects (also part
of assumption 1). Assumption 2 is not justified, be-
cause the arrows from U to S and U to Y imply
that the effect of S on Y is confounded.
The joint effects of A and S are, in principle, iden-
tifiable without making modeling assumptions in an
experiment in which both factors (e.g., blood pres-
sure treatment and kidney function) are experimen-
tally controlled and both treatments assigned ran-
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domly. Kidney function might be controlled experi-
mentally by surgery. Ethical considerations preclude
performing such experiments in humans; animal ex-
perimentation could, in principle, be used to learn
about the direct effect of blood pressure control.
Model (9) is fairly simple and might not be a
faithful representation of the real-world situation.
In particular, the effects A and S in (9) might vary
with observed covariates (e.g., baseline covariates
X or observed treatment levels A) or latent covari-
ates (e.g., the principal strata). Approaches for deal-
ing with these issues (Robins, 1999; Robins, Rot-
nitzky and Scharfstein, 2000; van der Laan and Pe-
tersen, 2004; Robins, 2003) are beyond the scope of
this paper.
7.2.3 Explanation and generalization. Explanatory
analysis can serve to explain the findings in the data
at hand in ways which may generalize further to
other populations or settings, a more ambitious task
requiring further assumptions. Generalizability be-
yond one’s data is enhanced if the relations found in
one’s data are likely to hold in other settings. Two
strategies for this are:
1. Obtaining a finer understanding of the causal
processes leading from treatment to outcome. With
sufficiently detailed and accurate understanding, al-
tering one component in the causal system may not
change the other causal mechanisms in the system;
this may allow better prediction of the effects of
interventions in other settings (Pearl, 1995, 2000).
Partitioning effects into component direct and indi-
rect effects is an attempt to obtain understanding
in those terms.
2. Estimating the effects of treatment for homoge-
nous subgroups in which causal effects in the popu-
lation under study can be assumed to be similar to
like groups in other populations. This can be done
by estimating the effects of treatment for subgroups
defined by observable variables X or S, or by the la-
tent principal strata S. Principal stratification can
lead to a finer partition of the population than strat-
ification on observed variables alone, and so can po-
tentially lead to more generalizable conclusions.
These strategies are not mutually exclusive. Struc-
tural nested models have been formulated in a way
which recognizes possible differences in effect in sub-
groups not identifiable at baseline (Robins et al.,
1992; Robins, Rotnitzky and Scharfstein, 2000); our
approach to using G-estimation for estimating treat-
ment effects for strata defined by observed post-
treatment auxiliaries allows finer stratification. Fur-
ther, PS approaches have been used in conjunc-
tion with approaches which allow one to consider
partitioning causal effects (Angrist, Imbens and Ru-
bin, 1996).
8. FUTURE WORK: EXTENSIONS OF
ESTIMANDS AND ESTIMATION
We conclude the paper with a discussion of various
additional complications which may arise in applied
problems, and outline possible directions for future
work in this context.
8.1 Multiple Types of Auxiliary Variables
In considering conditioning on a post-treatment
auxiliary S, we have so far considered settings in
which the outcome of interest Y is meaningful for
all levels of S. Sometimes, the outcome of interest
Y is not defined at some levels of S. Most notably,
if S is (or includes) an indicator of vital status, the
outcome Y may not be defined meaningfully for sub-
jects who die, and so the effect of A on Y (i.e., the
contrast of Y 1 and Y 0) will be defined only for sub-
jects who would live whether or not treated (i.e.,
the principal stratum in which S1 = S0 = 1, where
S = 1 indicates being alive).
In the nephrology example, some subjects may de-
velop ESRD only if their blood pressure is treated
aggressively, because aggressive treatment may pre-
vent mortality. Thus, a simple version of the mono-
tonicity assumption stating that aggressive treat-
ment never causes ESRD will not be true. Because
of countervailing biases, the direction of bias of the
naive approach (comparing among treated and un-
treated subjects who develop ESRD) may not be
predictable.
Where there is a composite auxiliary variable (e.g.,
death and ESRD), there are several possible esti-
mands. Let S1 denote an auxiliary variable for which
outcomes are well defined at all values of the vari-
able (e.g., ESRD), and let S2 denote an auxiliary
variable for which outcomes are well defined only for
one value of the variable (e.g., death; S2 = 1 if a sub-
ject lives, 0 if dead). Because other outcomes are not
meaningfully defined for people who die (Frangakis
and Rubin, 2002; Kalbfleisch and Prentice, 2002),
it is difficult to ignore mortality in defining causal
estimands for this setting. This leaves fewer options
for dealing with mortality: looking at the effect of
treatment on the conditional distribution of Y given
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survival, and PS. Within the framework of PS for
mortality, almost any of the solutions above for the
other auxiliary variable (ESRD) may be applied for
defining causal estimands. The possible estimands
include comparisons of the following expectations
for different levels a of treatment:
1. E(Y a|S02 = 1, S
1
2 = 1), the effect of treatment for
subjects who would not die whether or not treated.
2. E(Y a|Sa2 = 1), the effect of treatment on the ex-
pectation of MI for subjects who would not die
under that treatment. As before (Section 2.2),
this is not a comparison of outcomes for a com-
mon set of subjects. This estimand is most eas-
ily understood in conjunction with the effect of
treatment on survival [i.e., comparisons of E(Sa2 )].
This and the previous estimand are not defined
in terms of ESRD. Estimands which use ESRD
include:
3. E(Y a|Sa1 = 1, S
a
2 = 1), the effect of treatment on
the distribution of MI among subjects who would
be alive and have ESRD under that treatment;
4. E(Y a|S01 = 1, S
1
1 = 1, S
0
2 = 1, S
1
2 = 1), the effect of
treatment among subjects who, under both treat-
ment levels, would be alive and develop ESRD
(full or dual PS);
5. E(Y a|S11 = 1, S
0
2 = 1, S
1
2 = 1), the effect of treat-
ment on subjects who would live whether or not
treated and develop ESRD if treated (single po-
tential auxiliary stratification for S1 in conjunc-
tion with PS for S2);
6. E(Y a|S1 = 1, S
0
2 = 1, S
1
2 = 1,A= 1), the effect of
treatment on subjects who would live whether or
not treated, who are treated and develop ESRD
(observed auxiliary stratification); and
7. E{Y a|E(S01 |X), S
0
2 = 1, S
1
2 = 1,A= 1}, the effect
of treatment on subjects at a particular risk of
ESRD who would live whether or not treated.
We expect that the likelihood-based or sensitivity
analysis methods mentioned in Section 4.4 could be
extended to deal with these issues and estimands.
8.2 Other Extensions
Many real-world problems, including studying the
effect of the aggressive management of blood pres-
sure on renal patients, involve problems that are
substantially more complicated than those consid-
ered here. Complications arise from the fact that all
three main variables under study (i.e., treatment A,
auxiliary variable S and outcome Y ) may be more
complex than the simple binary variables we have
discussed. The additional complexity of each may
require refinement or redefinition of the effects un-
der study as well as of the methods used to estimate
them.
The auxiliary variable S of interest may, in fact, be
measured repeatedly over time. In the renal study,
the time ESRD develops will be noted; in the HIP
study, the time of breast cancer diagnosis will be
noted. For such a failure-time variable S, one could
define effects of treatment based on the actual failure-
time [e.g., compare E(Y a|S1, S0) for different a], or
on whether the failure-time exceeds some threshold
[e.g., compare E{Y a|I(S1 > s), I(S0 > s)} for dif-
ferent a]. For failure-time outcomes, as in the HIP
study, we can revise the causal estimand to account
for the timing of changes in the auxiliary variable.
Let S(t) = 1 after a subject with breast cancer is
diagnosed by screen, 0 otherwise (a modification
of the third definition of S in Section 6). A ver-
sion of the accelerated failure-time model with time-
varying covariates [a generalization of (4)] is T 0 =∫ T
0 exp{AS(t)Ψ}dt (Cox and Oakes, 1984; Robins,
1992; Robins et al., 1992), where T is the subject’s
failure time and T 0 the failure-time if the subject
had not been screened. The causal parameterΨ now
represents the effect of screening in shortening time
from cancer diagnosis to mortality among screen-
diagnosed subjects. G-estimation could be applied
for estimating parameters in this model.
Similarly, the outcome variable Y may be a re-
peated measures outcome. This allows many options
for the time that the value of the auxiliary variable is
measured: one may be interested in defining effects
of treatment conditional on the value of the auxil-
iary variable at the time the outcome Y is measured,
or one year previously, or on the time of failure for a
failure-time auxiliary such as ESRD. If the outcome
is defined at all levels of the auxiliary, all options are
potentially meaningful. We expect that any of the
methods for defining and estimating causal quanti-
ties sketched above (Sections 3 and 4) could apply.
The study exposure or treatment is often not a
simple scalar but may vary over time, and the joint
effects of treatments received at different points in
time may be of interest; this is true of observa-
tional studies of the effect of aggressive manage-
ment of blood pressure, in which therapy is pro-
vided over an extended period and changes may be
made over that time. Robins (Robins, Rotnitzky and
Scharfstein, 2000) has provided a general approach
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to defining the component and joint effects of treat-
ments given over an extended period; this approach
would need to be generalized to allow the effects of
a component of treatment or of a treatment plan
to depend on auxiliary variables subsequent to the
treatment. For defining the component effect of a
treatment At applied at t, we might want to allow
the effect to depend on St+1, for example. Alter-
natively, we might want to allow the joint effect of
the component treatments in a prespecified regime
to depend on the level of an auxiliary variable that
applies at a fixed point in time after the start of
follow-up.
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